Regenerative Medicine

AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development | Benzinga | 11/13/2019

AVITA Medical ((ASX: AVH, NASDAQ: RCEL ), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial growth strategy. The Institutional Placement was managed by Bell Potter as …

Biogelx announces R&D and distribution collaboration with Regemat3D | 11/13/2019

View Supplier Profile Nov 12 2019 Regemat3D and Biogelx announce R&D and distribution collaboration to offer complete bioprinting solutions for research institutes worldwide. Regemat3D has been manufacturing bioprinting systems and regenerative medicine solutions from 2011. The company along with research collaborators is developing clinical and pre-clinical models from cartilage and skin regeneration to living tissues in over 20 countries. As part of the new collaboration agreement with Biogelx …

Follow Regenerative Medicine:    

Personalized Stem Cells, Inc. Announces First Patients Treated in FDA… | PRWeb | 11/13/2019

… offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patient’s own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing cGMP manufactured, quality tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine

Visionary Chris Olver Named Executive Director of Cerebral Palsy Alliance Research Foundation | PRWeb | 11/13/2019

Cerebral Palsy Alliance Research Foundation (CPARF) is thrilled to announce the appointment of Chris Olver as its new Executive Director. Chris is a nonprofit leader with proven fundraising and storytelling track records with mission-driven organizations on three continents. “Chris brings a special medley of skills, longtime nonprofit experience, and passion that will serve us well as we continue to build CPARF into a global research leader in the cerebral …

Interleukin-6 from Adipose-Derived Stem Cells Promotes Tissue Repair by the Increase of Cell Proliferation and Hair Follicles in Ischemia/Reperfusion-Treated Skin Flaps | 11/13/2019

… innovative therapies to reduce ischemia/reperfusion (I/R) injuries [ 4 ]. Stem cell-based therapies for I/R injury are a new field of medicine for regenerating tissues [ 5 ]. One adult stem cell candidate for regenerative medicine resides in the adipose tissue [ 6 , 7 ]. Adipose-derived stem cells (ADSCs) are found in adipose stromal tissues and are multipotent stem cells that are capable of differentiating into multiple mesenchymal lineages [ 6 ]. Recently …

(USA) Scientific Manager, Medicine by Design- 14 Month Term | 11/13/2019

… us:_ Medicine by Design harnesses the exceptional expertise at the University of Toronto and its affiliated hospitals at the convergence of physical and life sciences, engineering, mathematics and medicine to undertake transformative research in regenerative medicine and cell therapy. Funded by the single largest research award in U of T’s history, it fosters unique multidisciplinary collaborations and applies engineering design principles and quantitative biological modelling to accelerate breakthroughs. Through strategic …

Regenerative Medicine Market Share 2019 In-Depth Analysis of Industry Growth, Trends & Forecast up to 2025 | 11/13/2019

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies PUNE, INDIA, November 13, 2019 / EINPresswire.com / – The report provides a comprehensive analysis of the Regenerative Medicine industry market by types, applications, players and regions. This report also displays the 2014-2025 production, Consumption, revenue, Gross margin, Cost, Gross, market share, CAGR, and Market influencing factors of the Regenerative Medicine industry in USA, EU …

Oleg Svanidze Appointed as Chief Medical Officer | PR Newswire | 11/13/2019

Sverige Oleg Svanidze Appointed as Chief Medical Officer Seasoned medical device industry professional, Dr. Svanidze has a background in clinical cardiac surgery and extensive industry experience in clinical and medical affairs News provided by Nov 13, 2019, 08:34 MILAN , Nov. 13, Newronika, a spin-off of world-class neurological research center Policlinico of Milan and University of Milan , has appointed Dr. Oleg Svanidze MD, PhD as a Chief Medical Officer …

ISSCA Set to Host Upcoming Stem Cells Conferences, Reaching Physicians Across the Globe | 11/13/2019

… their practices to join us at one of our upcoming conferences,” said Benito Novas, Vice President of Public Relations for ISSCA. “Attendees will learn from highly trained physicians and researchers in the field of regenerative medicine and take away the necessary education and tools to implement the latest stem cells therapies into their own practices.” The ISSCA is a global leader in stem cells research, applications, and education, partnering with …

Global Regenerative Medicine Market to Grow Over $81 Billion by 2023 and Market Driven by Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries - ReportsnReports | PR Newswire | 11/13/2019

PUNE, India This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. The analysis indicates that the global Regenerative Medicine Market was worth $28 billion in 2018 and will grow to over $81 billion by 2023, with a CAGR of 23.3 …

The Cell and Gene Therapy Market to Reach Revenues of Over $6.6 billion by 2024 - Market Research by Arizton | PR Newswire | 11/13/2019

… also comparably high utilization and wide accessibility of these therapies. In Europe , cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally. The major factors leading to the growth in APAC region are the growing prevalence of cancers, osteoarthritis, burns, and other chronic wounds, the introduction of advanced products in Japan , advanced R&D activities …

Regenerative Medicine Market will Experience a Noticeable Growth During the Forecast period 2019 – 2027 | Integra LifeSciences Corporation, Gilead Sciences, Novartis, Vericel Corporation, Wright Medical | 11/13/2019

… 2027 Integra LifeSciences Corporation, Gilead Sciences, Novartis, Vericel Corporation, Wright Medical Regenerative medicine involves the generation and use of therapeutic stem cells, tissue engineering and the production of artificial organs. Major focus in the regenerative medicine fields are cellular therapies, tissue engineering & biomaterials, and medical devices and artificial organs. Along with replacement of damaged organs, regenerative medicine also helps with the regeneration of the organs. The “ The Insight Partners “ market …

Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights | Business Wire | 11/13/2019

… CD45: On November 11 th, 2019, Magenta announced that it had exercised its option with Heidelberg Pharma for exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD45. Received Regenerative Medicine Advanced Therapies (RMAT) Designation for MGTA-456 in inherited metabolic disorders: In September 2019, Magenta announced that the FDA granted RMAT designation for MGTA-456, a one-time cell therapy for the treatment of …

Orig3n Announces Customized Vitamin Partnership with VitaminLab and Launch of New Vitamin Genetic Test Kit | PR Newswire | 11/13/2019

… tissue damage and treating disease. Since its inception in 2014, Orig3n has built the largest suite of direct-to-consumer genetic tests on the market, and the world’s most comprehensive cell bank for commercial regenerative medicine applications. For more information, visit www.orig3n.com . About VitaminLab VitaminLab is a Canadian-based personalized vitamin company that was established in 2015 to provide individuals with a personalized supplement based on actionable health data, including …

Lonza Partners with Cryoport and Strengthens its Vein-to-vein Delivery Network in Cell & Gene Therapy | 11/13/2019

… network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport’s logistics and bioservices solutions with Lonza’s manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in …

Hypoxic Preconditioning Enhances Survival and Proangiogenic Capacity of Human First Trimester Chorionic Villus-Derived Mesenchymal Stem Cells for Fetal Tissue Engineering | 11/12/2019

… autologous MSC source [ 31 , 32 ], as chorionic villus sampling (CVS) can be performed in early gestation to obtain fetal stem cells. It has been shown that first trimester fetal MSCs possess several advantages for regenerative medicine over adult and perinatal MSCs [ 33 – 37 ]. Therefore, isolation of MSCs from first trimester chorionic villus tissue (CV-MSCs) that allows for therapeutic use for in utero applications represents a promising approach for autologous …

NanoRobotics Market expected to reach $11.88 Billion by 2026 with CAGR of 12.5% – Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik | 11/12/2019

Press Releases NanoRobotics Market expected to reach $11.88 Billion by 2026 with CAGR of 12.5% – Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik The Global Nanorobotics Market is accounted for $4.10 Billion in 2017 and is expected to reach $11.88 Billion by 2026 growing at a CAGR of 12.5% during the forecast period. Growing application of nanotechnology and regenerative medicine, rising acceptance and preferment of …

Intra-Bone Marrow Administration of Mesenchymal Stem/Stromal Cells Is a Promising Approach for Treating Osteoporosis | 11/12/2019

… marrow administration of pure MSCs is a safer and more effective approach for treating osteoporosis. 1. Introduction Mesenchymal stem/stromal cells (MSCs) have attracted much interest as potent somatic stem cells for use in regenerative medicine in various tissues/organs because of their ability to differentiate into multiple lineages (osteogenic, chondrogenic, adipogenic, myogenic, and neurogenic) [ 1 , 2 ]. MSCs have recently gained attention as immunosuppressive cells that may be effective for …

Intrexon Reports Third Quarter 2019 Financial Results | PR Newswire | 11/12/2019

GERMANTOWN, Md. Intrexon Corporation (NASDAQ: XON ), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its third quarter financial results for 2019. Recent Business Highlights: In Intrexon Health: Precigen, Inc., a wholly owned subsidiary of Intrexon, continues to advance its clinical and pre-clinical portfolios. Details about Precigen accomplishments will be highlighted during a conference call and …

Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights | Globe Newswire | 11/12/2019

… that MB-107, the lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, being developed by our partner company Mustang Bio, was granted the Regenerative Medicine Advanced Therapy (“RMAT”) designation by the U.S. Food and Drug Administration (“FDA”). We look forward to the presentation of additional clinical data on MB-107 at the upcoming 61 st ASH Annual Meeting and …

National Institutes of Health

Regular use of prescription drugs for pain and sleep increases frailty risk by 95 percent | 11/14/2019

… sleep drugs.” The HRS dataset used by the researchers is sponsored by the National Institute on Aging (NIA) of the National Institutes of Health and the Social Security Administration (SSA) and is conducted by the … strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAU’s existing strengths in research and scholarship …

NCMS Morning Rounds 11-13-19 | 11/13/2019

National Institutes of Health (NIH) grant for Integrative Training in Trauma and Regenerative Medicine, as well as a joint project with Wake Forest School of Medicine and the National Highway Traffic Safety Administration that established a Crash Injury Research and Engineering Network Center of Wake Forest and Virginia Tech, Blacksburg. Congratulations, Dr. Meredith, on being elected to this important position! In the News CDC: Gap Between Rural and Urban Deaths …

Clinical Research

Global Regenerative Medicine Market to Grow Over $81 Billion by 2023 and Market Driven by Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries - ReportsnReports | PR Newswire | 11/13/2019

PUNE, India This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of … also the level of investment required to support R&D, clinical research, trials and commercialization. Reimbursement strategies are also paramount to success of the overall space. There are over 700 regenerative medicine companies globally at …

Gerstner Regenerative Medicine Initiative: Tracking outcomes and supporting clinical trials | 11/12/2019

Gerstner Regenerative Medicine Initiative: Tracking outcomes and supporting clinical trials By Jennifer Schutz Outcomes registry tablet used during consults. One of the challenges of integrating regenerative medicine into daily patient care is that it is … also using this information to inform patients about regenerative options. “Clinical research trials are tightly controlled and often start with small patient numbers which will exclude a larger representation of our patient population,” says Dr …

Department of Health and Human Services

U.S. Health and Human Services Secretary Names Maria Ordonez to Alzheimer’s Council | 11/13/2019

… excited to join this group of highly experienced members who will continue the council’s great work in assisting our U.S. Department of Health and Human Services with further progress on the national plan for Alzheimer’s … strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAU’s existing strengths in research and scholarship …

Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections | PR Newswire | 11/11/2019

… in Dublin, Ireland , is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands … in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OTA number HHSO100201500029C …

Pain Management

Dr. John V. Prunskis, co-founder and co-Medical Director of the Illinois Pain Institute meets with Top White House Adviser | PRWeb | 11/11/2019

… founder and co-Medical Director of the Illinois Pain Institute, Presidential Appointee U.S. Department of Health and Human Services’ (HHS) Pain Management Best Practices Task Force (Pain Task Force) met last Monday with Joe Grogan … as well as contributing to the opioid crisis. Advancements in Regenerative Medicine and current research which was supported in the Pain Task Force report was also discussed. Dr. Prunskis, who is Hon. Consul of Lithuania …

Dr. John Prunskis travels to White House for discussion on opioid crisis | 11/8/2019

Pain Management Best Practices Task Force, travelled to the white house to discuss solutions to the opioid crisis and other healthcare challenges on Nov. 4. Four things to know: 1. Dr. Prunskis met with Joe Grogan, assistant to the President of the United States and director of the domestic policy council. 2. Other healthcare topics on the agenda were advances in regenerative medicine and EHR challenges, which have been linked …

Pain Management

Dr. John V. Prunskis, co-founder and co-Medical Director of the Illinois Pain Institute meets with Top White House Adviser | PRWeb | 11/11/2019

… founder and co-Medical Director of the Illinois Pain Institute, Presidential Appointee U.S. Department of Health and Human Services’ (HHS) Pain Management Best Practices Task Force (Pain Task Force) met last Monday with Joe Grogan … as well as contributing to the opioid crisis. Advancements in Regenerative Medicine and current research which was supported in the Pain Task Force report was also discussed. Dr. Prunskis, who is Hon. Consul of Lithuania …

Dr. John Prunskis travels to White House for discussion on opioid crisis | 11/8/2019

Pain Management Best Practices Task Force, travelled to the white house to discuss solutions to the opioid crisis and other healthcare challenges on Nov. 4. Four things to know: 1. Dr. Prunskis met with Joe Grogan, assistant to the President of the United States and director of the domestic policy council. 2. Other healthcare topics on the agenda were advances in regenerative medicine and EHR challenges, which have been linked …

Patient Safety

PRP Science Expands Product Offering to Include FDA Approved Products and Devices | PRWeb | 11/11/2019

… the EXCEED device because of its exceptional precision and versatility, research proven efficacy and engineering, dual FDA clearance and superior patient safety.” Said Rank Barone, MD, FACS, board certified plastic surgeon and founder of Evolv … focus on improving patient lives and advancing the field of regenerative medicine.” Said Jill Swartz, President of PRP Science. “We help eliminate the learning curve for our clients, vetting the leading systems, diagnostics, pre and …

Cryoport Revenue Grows 81% for Third Quarter 2019 | PR Newswire | 11/7/2019

… and near real-time monitoring. This partnership provides end-to-end solutions for advanced therapies, supporting improved product quality and patient safety. “Other recent announcements include a three-year agreement with Adaptimmune Therapeutics plc, to … as the market grows. “Data provided by the Alliance for Regenerative Medicine states that there are five anticipated BLA or MAA submissions in the remainder of 2019 or early 2020 for therapies supported by Cryoport …

Medical Education

New Orleans’ Precision-Medicine Physician Becomes Certified in the Clinical Use of Peptides | PRWeb | 11/11/2019

Infinite Health Integrative Medicine Center’s, Founder/CEO, Trip Goolsby, MD attended Age Management Medicine Group’s (AMMG) November Continuing Medical Education Conference in Tucson, Arizona, November 7th, and received a certification in the clinical use of … medicine practice with a niche focus on health optimization, longevity & regenerative medicines, “…incorporating the age-management benefits of peptide therapies into our current programs and modalities just makes sense,” Dr. Goolsby stated. “Peptides are essentially …

Senior Researcher in translational medicine and therapeutics for leukemia | Nature | 11/8/2019

… leukemia Karolinska Institutet (KI) Posted about 12 hours ago Expires on December 06, 2019 Division The Center for Hematology and Regenerative Medicine ( HERM ) is a research unit within the Department of Medicine Huddinge with a … conduct successful medical research and hold the largest range of medical education in Sweden. Karolinska Institutet is a state university, which entitles to several benefits such as extended holiday and generous occupational pension. Employees also …

American Heart Association

The Week Ahead In Biotech: Adcom Test For Amarin’s Fish Oil Pill, Agile Awaits FDA Verdict | Yahoo News | 11/11/2019

… College of Rheumatology, or ACR, /ARP 2019 Annual Meeting: Nov. 8-13 in Atlanta, Georgia 12th International Conference on Tissue Engineering & Regenerative Medicine: Nov. 11-12 in Madrid, Spain 28th Annual Credit Suisse Healthcare Conference: Nov. 11-13 … Paris, France 33rd European Ophthalmology Congress: Nov. 14-15 in Madrid American Heart Association Scientific Sessions 2019: Nov. 16-18 in Philadelphia, Pennsylvania Related Link: Aimmune CFO On Peanut Allergy Candidate Palforzia: ‘There Is A Serious Unmet …

Clinical Data

How to create a strategic business plan to ensure success under MDR/IVDR | Medical Design and Outsourcing | 11/9/2019

… medical devices currently on the EU market will need to be recertified. Companies will have to submit vast amounts of clinical data in addition to implementing comprehensive post-market surveillance assessments and reporting. Also, there … regions may be more attractive for some devices, particularly in regenerative medicine. C-suite involvement C-suite executives may play a critical role in preparing your business for success under MDR and IVDR. To engage …

Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting - GuruFocus.com | 11/8/2019

… submit, obtain and maintain FDA or other regulatory authority approval of, or other action with respect to, our product candidates, including those product candidates that have been granted breakthrough therapy designation (“BTD”) or regenerative medicine advanced therapy designation (“RMAT”) by the FDA and new product candidates in both solid tumor and blood cancers; the strength of the Company’s product pipeline; the successful implementation of the Company’s research and development programs …

Food and Drug Administration

AVITA Medical Added to S&P/ASX 200 Index | Business Wire | 11/8/2019

… Index 12 hrs ago VALENCIA, Calif. & MELBOURNE, Australia–(BUSINESS WIRE)–Nov 7, 2019– AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic … U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 …

Induced Pluripotent Stem Cells Market Increasing At A Compound Annual Growth Rate (CAGR) Of 11.6% From 2016 Through 2021 | 11/7/2019

… this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell … encouraging the marketing of stem cells, including iPSCs.– The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinson’s …

Allergan

Parallel Advisors LLC Raises Holdings in Allergan plc (NYSE:AGN) | 11/11/2019

Parallel Advisors LLC Raises Holdings in Allergan plc (NYSE:AGN) Posted by Lisa Pomrenke on Nov 10th, 2019 Parallel Advisors LLC lifted its stake in Allergan plc (NYSE:AGN) by 151.3% during the third quarter … develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in …

Golub Group LLC Has $56.34 Million Holdings in Allergan plc (NYSE:AGN) - TheOlympiaReport | 11/11/2019

Golub Group LLC cut its stake in Allergan plc (NYSE:AGN) by 2.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 334,786 shares … develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in …

Thermo Fisher

Biotechnology Market Size Worth $741.7 Billion by 2026 | CAGR 7.7% | 11/11/2019

… to invest and conduct R&D activities at a broader scale. Another factor which is helping the market growth includes regenerative medicines. Existence of a huge section of businesses concentrating on the advancement of regenerative … Laboratories, Danaher, F. Hoffmann-La Roche, Illumina, Merck, PerkinElmer, Qiagen, Thermo Fisher Scientific, Gilead, Celgene, Novo Nordisk A/S, Novartis AG, Sanofi Aventis, and Lonza. ABOUT US -Polaris Market Research is a global market research …

Biological Safety Testing Market Outlook: Industry Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2025 | 11/11/2019

… need to be free from adventitious agents to avoid proliferation of fatal infections. Thus, growing application of stem cells in regenerative medicine will thereby increase the demand for biological safety testing. Pharmaceuticals & biopharmaceutical companies segment … operating biological safety testing market are Eurofins Scientific, Merck KGaA, Thermo Fisher Scientific, Esco, and Wuxi Biologics, among several others. More Details on this Report At: https://www.marketstudyreport.com/reports/biological-safety-testing-market About Us …

Novartis

The Week Ahead In Biotech: Adcom Test For Amarin’s Fish Oil Pill, Agile Awaits FDA Verdict | Yahoo News | 11/11/2019

… earnings reports from small- to mid-sized biotechs. The FDA approved Sanofi SA’s (NASDAQ: SNY ) Fluzone for older adults and Novartis AG’s (NYSE: NVS ) Sandoz unit’s Neulasta biosimilar. REDHILL BIOPHAR/S ADR (NASDAQ: RDHL )’s … 8-13 in Atlanta, Georgia 12th International Conference on Tissue Engineering & Regenerative Medicine: Nov. 11-12 in Madrid, Spain 28th Annual Credit Suisse Healthcare Conference: Nov. 11-13 in Scottsdale, Arizona 13th International Congress on Autoimmunity: Nov. 12-13 …

Cryoport: Cold Chain Is A Hot Business Model - Cryoport, Inc. (NASDAQ:CYRX) | Seeking Alpha | 11/11/2019

… main growth driver over the past four years has been related to biopharmaceuticals, which is experiencing tremendous growth in the regenerative medicine segment. This area includes cell therapy, gene therapy and gene-based therapy. According … currently the sole source logistics supplier to Gilead ( GILD ) and Novartis ( NVS ) for Yescarta and Kymriah, respectively, and it will be involved with the 2020 introduction of bluebird bio’s ( BLUE ) Zynteglo. Additionally, and in my …

Pfizer

Orthobiologics Market Aggregate Insights | Market Forecast to 2026 | 11/11/2019

… provide a tool that allows physicians conducting autologous injection therapies.• In May 2019, Anika Therapeutics, a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced … BMP portfolio of development programs and associated intellectual property from Pfizer, in 2013. The portfolio, which will now be sold to VB, includes the next-generation BMP in development, as well as a BMP program …

Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For Antibiotic-Resistant Gram-Negative Infections | PR Newswire | 11/11/2019

… for patients with these infections. ATM-AVI is currently in Phase III trials. ATM-AVI is being jointly developed with Pfizer. Allergan holds the rights to commercialize ATM-AVI in North America , while Pfizer holds … developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key …

Merck

Biotechnology Market Size Worth $741.7 Billion by 2026 | CAGR 7.7% | 11/11/2019

… to invest and conduct R&D activities at a broader scale. Another factor which is helping the market growth includes regenerative medicines. Existence of a huge section of businesses concentrating on the advancement of regenerative … Instruments, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Illumina, Merck, PerkinElmer, Qiagen, Thermo Fisher Scientific, Gilead, Celgene, Novo Nordisk A/S, Novartis AG, Sanofi Aventis, and Lonza. ABOUT US -Polaris Market Research is a …

Biological Safety Testing Market Outlook: Industry Growth Factors, Applications, Regional Analysis, Key Players and Forecasts by 2025 | 11/11/2019

… need to be free from adventitious agents to avoid proliferation of fatal infections. Thus, growing application of stem cells in regenerative medicine will thereby increase the demand for biological safety testing. Pharmaceuticals & biopharmaceutical companies segment … Major players operating biological safety testing market are Eurofins Scientific, Merck KGaA, Thermo Fisher Scientific, Esco, and Wuxi Biologics, among several others. More Details on this Report At: https://www.marketstudyreport.com/reports/biological-safety-testing-market …

AbbVie

Expert commentary: Longevity – investing in the future | Hill Dickinson | 11/6/2019

… for people to live longer, healthier lives – whether by slowing, stopping or potentially reversing the ageing process. Ageing research and regenerative medicine is expected to grow into a multi-trillion dollar industry over the next … on a US$2.5 billion collaboration with US pharmaceutical company, AbbVie, in Calico’s labs in San Francisco, the largest known research project looking at lifespan extension. A series of mega-deals in 2018 sparked the …

Allergan Reports Third Quarter 2019 Financial Results | PR Newswire | 11/5/2019

… revenues in the third quarter of 2019 were $134.8 million , an increase of 6.0 percent versus the prior year quarter. Regenerative Medicine ALLODERM ® net revenues in the third quarter of 2019 were $95.0 million , a … follow in the first half of 2020. UPDATE ON PROPOSED ABBVIE TRANSACTION On October 14, 2019 , Allergan shareholders voted to approve the proposed acquisition of Allergan by AbbVie. Additionally, both companies received a Request for …

GE Healthcare

Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. | PR Newswire | 11/5/2019

… Market Insights, Inc. Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market’s growth. The government often implements several laws and initiatives to motivate scientists … global market are Abbott, Roche, Siemens Healthcare, Danaher Corporation, Becton, GE Healthcare, Dickinson and Company (BD), Janssen Diagnostics among others. https://www.gminsights.com/industry-analysis/cancer-diagnostics-market About Global Market Insights Global Market Insights, Inc …

Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. | The Wapakoneta Daily News | 11/5/2019

… Market Insights, Inc. Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market’s growth. The government often implements several laws and initiatives to motivate scientists … global market are Abbott, Roche, Siemens Healthcare, Danaher Corporation, Becton, GE Healthcare, Dickinson and Company (BD), Janssen Diagnostics among others. https://www.gminsights.com/industry-analysis/cancer-diagnostics-market About Global Market Insights Global Market Insights, Inc …

BioLife

BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 | Benzinga | 11/1/2019

BOTHELL, Wash. , Oct. 31, 2019 /PRNewswire/ – BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, (“BioLife” or the “Company”), today announced that the … HypoThermosol ® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation …

Medtronic

Global Orthobiologics Market – Segmented by Product, Application, End User, and Geography – Growth, Trends, and Forecast (2019 – 2024) | Financial Buzz | 11/1/2019

… Increasing Patient Preference for Minimally Invasive Procedures Orthobiologic therapy is a minimally invasive therapy and one of the components of regenerative medicine that are used to treat several musculoskeletal ailments, including degenerative osteoarthritis. Lately, orthobiologics … Terumo Bct Company) K2M Group Holdings, Inc. Kuros Biosciences Ltd Medtronic PLC. Nuvasive, Inc. Orthofix International NV RTI Surgical Inc. Seaspine Holdings Corporation Reasons to Purchase the Orthobiologics Market Report – Current and future orthobiologics market …

Global Cell Encapsulation Research Report 2019-2030 | PR Newswire | 10/30/2019

… Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure … of South Carolina Medicyte MediGene MedImmune MEDINET Medipost Mediso Medpace Medtronic MedVax Technologies Medytox Merck Serono Mesoblast Michael J Fox Foundation for Parkinson’s Research MicroMecha Miltenyi Biotec Minovia Therapeutics Moderna Therapeutics MolecuVax MolMed Moraga Biotechnology …

Celgene

Stem Cell Market Estimated to Value $15.63 Billion By 2025 | 11/1/2019

… is expected open up new avenues of market expansion over the forecast period. Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years. Regenerative medicine is set to … Asia Pacific market in the forthcoming years Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players The companies are undergoing strategic …

Stem Cell Market Strategy, Distributors & Manufacturing Cost Analysis Till 2025 | 11/1/2019

… is expected open up new avenues of market expansion over the forecast period. Rapid transition from conventional treatment methods to regenerative medicine has been observed over the past few years. Regenerative medicine is set to … Asia Pacific market in the forthcoming years Osiris Therapeutics Inc.; Celgene Corporation; BIOTIME, INC.; Cynata; Advanced Cell Technology Inc.; and STEMCELL Technologies Inc.; are some of the key market players The companies are undergoing strategic …

Maxim Group

Mesoblast limited (NASDAQ:MESO) Expected to Announce Quarterly Sales of $16.41 Million | 11/2/2019

… equity of 17.66% and a negative net margin of 536.97%. A number of analysts have issued reports on the company. Maxim Group reissued a “buy” rating and issued a $16.00 target price on shares of … biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials …

BioCardia (OTCMKTS:BCDA) Stock Price Down 5.1% | 11/2/2019

… research note on Tuesday, September 17th. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, Maxim Group began coverage on shares of BioCardia in a research note on Thursday, October … quarter. About BioCardia ( OTCMKTS:BCDA ) BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and …

SVB Leerink

Atria Investments LLC Purchases New Stake in Allergan plc (NYSE:AGN) | 11/1/2019

… hold” rating and issued a $178.00 price target on shares of Allergan in a research note on Thursday, August 8th. Svb Leerink reiterated a “market perform” rating and issued a $188.00 price target (down from … develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in …

Retirement Systems of Alabama Sells 66 Shares of Allergan plc (NYSE:AGN) - Ticker Report | 11/1/2019

… Allergan from $172.00 to $189.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Svb Leerink reissued a “market perform” rating and issued a $188.00 price objective (down from … develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in …

Amgen Ventures

Global Cell Encapsulation Research Report 2019-2030 | PR Newswire | 10/30/2019

… 4D Pharma Aarhus University Hospital Acer Therapeutics Activartis Biotech Activate Immunotherapy Adaptimmune Adicet Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure Pharma Amgen Amphera AMVALOR Anhui Kedgene Biotechnology ANI Pharmaceuticals Anterogen apceth Biopharma Arbele ARCH Venture Partners Argos Therapeutics Asahi Glass Company ASAP …

Term Sheet – Thursday, November 9 | Fortune | 11/9/2017

regenerative medicine company, raised $25 million in Series B funding. Investors include Amgen Ventures. • Oyster Point Pharmaceuticals Inc. , a San Francisco-based developer of treatments for dry eye and other diseases of the ocular surface, raised $22 million in Series A funding. New Enterprise Associates and Versant Ventures led the round. • Broker Genius , a New York-based dynamic pricing technology for the secondary ticket market, raised $15 million in Series …

Morgan Stanley

Mesoblast limited to Post FY2020 Earnings of ($0.78) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:MESO) - Ticker Report | 10/27/2019

… quick ratio of 1.41 and a current ratio of 1.41. An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its position in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% during … biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company’s products under the Phase III clinical trials …

Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019 | BioSpace | 9/4/2019

Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019 BEDFORD, Mass.–( BUSINESS WIRE )– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that Joseph Darling, President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat at the 2019 Morgan Stanley

First Analysis

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 10/25/2019

Anika Therapeutics Inc. (NASDAQ: ANIK 5:00 Sylvia Cheung - CFO Joseph Darling - President & CEO Jim Sidoti - Sidoti & Company Joe Munda - First Analysis Brian Gagnon - Gagnon Securities Operator Good evening, ladies and gentlemen, and welcome to Anika … to deliver innovative products across the continuum of orthopedic and regenerative medicine therapies. As a testament to our team’s strong execution in the quarter, we successfully delivered double-digit revenue and earnings growth on the …

Anika Therapeutics’ (ANIK) CEO Joseph Darling on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… Cheung – Chief Financial Officer Joseph Darling – President and Chief Executive Officer Conference Call Participants Mike Petusky – Barrington Research Joe Munda – First Analysis Jim Sidoti – Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to … of innovative product launches across the continuum of orthopedic and regenerative medicine therapies. We achieved double digit revenue growth year-over-year in all product lines, including in both our U.S. and international viscosupplement businesses …

EW Healthcare Partners

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry | PR Newswire | 8/26/2019

… sponsor to support its short-term and long-term growth as it closed on a round of growth capital from EW Healthcare Partners (“EW Healthcare”). (PRNewsfoto/Cognate BioServices) “We have known Cognate and followed its … focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate provides a unique combination of custom services to companies across all points of clinical and …

TissueTech Raises $82 Million in Latest Round of Equity Financing | Markets Insider | Business Insider | 6/26/2019

MIAMI , June 26, 2019 /PRNewswire-PRWeb/ – TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbilical cord and amniotic membrane, today announced the closing of an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners (formerly Essex Woodlands) and followed by the third round of continuous investments from Ballast Point Ventures. The funds will primarily be used to pursue regulatory approvals from the FDA for several …

Versant Ventures

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

… held by Bayer, a German healthcare and nutrition business. In 2016, Bayer partnered with U.S. life sciences venture capital firm Versant Ventures in founding BlueRock with a US$225 million financing . Bayer said it will … leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock …

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Ballast Point Ventures

TissueTech Raises $82 Million in Latest Round of Equity Financing | Markets Insider | Business Insider | 6/26/2019

MIAMI , June 26, 2019 /PRNewswire-PRWeb/ – TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbilical cord and amniotic membrane, today announced the closing of an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners (formerly Essex Woodlands) and followed by the third round of continuous investments from Ballast Point Ventures. The funds will primarily be used to pursue regulatory approvals from the FDA for several …

MPM Capital

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT | Business Wire | 6/11/2019

Classifieds AP AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT 1 hr ago Save HOUSTON … investors are the UBS Oncology Impact Fund (OIF) managed by MPM Capital, as well as F2 Ventures. Investors also include EcoR1 Capital, Redmile Group, and Samsara BioCapital. For more information, please visit https://www.elevate.bio . View …

Cell Encapsulation Markets 2019-2023: Current Market Landscape and the Future Potential of Encapsulated Cell Therapies and Affiliated Technologies | PR Newswire | 5/29/2019

… Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure … Miltenyi Biotec Minovia Therapeutics Moderna Therapeutics MolecuVax MolMed Moraga Biotechnology MPM Capital Multimmune Mustang Bio Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering NantKwest National Cancer Institute National Center for Advancing Translational …

New Enterprise Associates

NEA Welcomes Scott Gottlieb, M.D., As Special Partner | BioSpace | 5/23/2019

NEA Welcomes Scott Gottlieb, M.D., As Special Partner CHEVY CHASE, Md. , May 22, 2019 /PRNewswire/ – New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the appointment of Scott Gottlieb , M.D., as … the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, and digital health devices; implemented new reforms to standardize drug and medical device reviews; and promoted policies to reduce death and …

Mayo Clinic

Patient-specific functional genomics and disease modeling suggest a role for LRP2 in Hypoplastic Left Heart Syndrome | 11/9/2019

… Regenerative Medicine, Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA; For correspondence: Timothy M Olson Department of Cardiovascular Medicine, Cardiovascular Genetics Research Laboratory, Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Department of Molecular and Pharmacology and Experimental Therapeutics, Mayo Clinic, Roc Preview PDF Abstract Background: Congenital heart diseases, such as hypoplastic left …

Helping Others Heal: Giving Them Their Voice | 11/7/2019

… store clerk is frustrating and can deliver looks of horror and pity. As an ear, nose and throat specialist at Mayo Clinic, Dr. David Lott , has seen laryngectomies impair too many lives. “I’m tired of … these people. And with the latest breakthroughs in transplant and regenerative medicine, he knows how. The first strategy Dr. Lott and his team at Mayo Clinic are a step ahead of the rest of the …

Massachusetts General Hospital

New Innovator Awards Go to Three Investigators | 11/5/2019

… MD, PhD Improving Kidney Replacement Therapy Ryuji Morizane, MD, PhD , is a principal investigator researching stem cell differentiation and kidney regenerative medicine. Dr. Morizane’s NIH Director’s New Innovator Award will help support his project developing … Institute Blog . The Research Institute: Saving Lives Through Science The Massachusetts General Hospital Research Institute is the largest hospital-based research program in the United States, with a community of more than 8,500 people working …

Thats a switch! Synthetic circuits regulate gene expression | 11/4/2019

… machinery of life opens exciting new avenues in chemical synthesis, intelligent drug design, energy production, environmental remediation, next-generation diagnostics, regenerative medicine and cancer therapy. The simplicity and versatility of RNA, composed of just 4 … and Women’s Hospital, Boston Children’s Hospital, Dana–Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zurich and Massachusetts Institute …

Memorial Sloan Kettering Cancer Center

Atara Biotherapeutics (NASDAQ:ATRA) versus AVITA MED LTD/S (NASDAQ:RCEL) Head-To-Head Survey - WKRB News | 11/3/2019

… Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers …

AVITA MED LTD/S (NASDAQ:RCEL) vs. Atara Biotherapeutics (NASDAQ:ATRA) Financial Review | 10/31/2019

… is 109% more volatile than the S&P 500. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt …

Moffitt Cancer Center

Atara Biotherapeutics (NASDAQ:ATRA) versus AVITA MED LTD/S (NASDAQ:RCEL) Head-To-Head Survey - WKRB News | 11/3/2019

… Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company’s patented and proprietary …

AVITA MED LTD/S (NASDAQ:RCEL) vs. Atara Biotherapeutics (NASDAQ:ATRA) Financial Review | 10/31/2019

… is 109% more volatile than the S&P 500. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California …

Memorial Sloan Kettering

AVITA MED LTD/S (NASDAQ:RCEL) vs. Atara Biotherapeutics (NASDAQ:ATRA) Financial Review | 10/31/2019

… is 109% more volatile than the S&P 500. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt …

AVITA MED LTD/S (NASDAQ:RCEL) vs. Atara Biotherapeutics (NASDAQ:ATRA) Head to Head Survey | 10/31/2019

… is 109% more volatile than the S&P 500. About AVITA MED LTD/S Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt …

University of Texas Southwestern Medical Center

Unlocking the black box of embryonic development | Phys Org | 10/31/2019

… Science on October 31, 2019, provide valuable insight into early embryonic development and potentially can help inform approaches to advance regenerative medicine in humans. “Our study provides a first look into this black box of … a co-author of the paper and assistant professor at University of Texas Southwestern Medical Center. “We wanted to monitor the embryos every day to observe their shape, size and migration patterns as well as …

Harvard Medical School

Hematologists, oncologists elected to National Academy of Medicine | 10/30/2019

… and head and neck cancer progression, metastasis, and therapy resistance. Daphne Adele Haas-Kogan, MD, professor of radiation oncology at Harvard Medical School and chair of the department of radiation oncology at Brigham and Women’s … with “real life” clinical applications in cancer diagnosis, prenatal diagnosis, regenerative medicine and tissue engineering. John Eu-Li Wong, MBBS, Isabel Chan professor in medical sciences and senior vice president for health affairs at National …

Emergent high fatality lung disease in systemic juvenile arthritis | BMJ | 10/4/2019

… Hospital , Wyoming , Michigan , USA 20 University of Michigan , Ann Arbor , Michigan , USA 21 Boston Children’s Hospital , Boston , Massachusetts , USA 22 Harvard Medical School , Boston , Massachusetts , USA 23 Pediatrics , Children’s Hospital of Los Angeles , Los Angeles … Massachusetts , USA 69 Medicine, Institute for Stem Cell Biology and Regenerative Medicine , Stanford University , Stanford , California , USA 70 Biomedical Data Science , Stanford University , Stanford , California , USA 71 Institute for Immunity, Transplantation and Infection, Microbiology and …

Medical University of South Carolina

Global Cell Encapsulation Research Report 2019-2030 | PR Newswire | 10/30/2019

… Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure … MaxCyte MaxiVAX Mayo Clinic McGill University MED-EL Medeor Therapeutics Medical University of South Carolina Medicyte MediGene MedImmune MEDINET Medipost Mediso Medpace Medtronic MedVax Technologies Medytox Merck Serono Mesoblast Michael J Fox Foundation for Parkinson’s …

Hematologists, oncologists elected to National Academy of Medicine | 10/30/2019

… Raymond N. DuBois Jr., MD, PhD, dean of the College of Medicine and professor of biochemistry and medicine at The Medical University of South Carolina. He discovered the critical and mechanistic role of prostaglandins/cyclooxygenase … with “real life” clinical applications in cancer diagnosis, prenatal diagnosis, regenerative medicine and tissue engineering. John Eu-Li Wong, MBBS, Isabel Chan professor in medical sciences and senior vice president for health affairs at National …

Sanford Health

(USA-ND-Fargo) RN, Clinical Research – Regenerative Medicine | Sanford Health | 10/16/2019

Job Title: RN, Clinical Research Regenerative Medicine Fargo City: Fargo State: ND Department : Regenerative Medicine Job Schedule: Full Time Shift: Days Hours Per Shift: 8 hr JOB SUMMARY Provides an opportunity to learn daily and … and subsequently maintains required department specific competencies and certifications. About Sanford Health: At Sanford Health, we are dedicated to the work of health and healing. Every day, we show that commitment by delivering the highest …

Hair grown through skin using stem cells in breakthrough that could cure baldness | Yahoo News | 6/28/2019

regenerative medicine field.” The not-for-profit Sanford Burnham Prebys Institute , based in California, is largely funded by Sanford Health, which helped Jack Nicklaus, the golfer, regain his swing through injections of stem cells in his back . The new technique uses a 3D biodegradable scaffold made from the same material as dissolvable stitches which controls the direction of hair growth and helps the stem cells integrate into the skin. Tests …

MD Anderson Cancer Center

World Cord Blood Day 2019 to Welcome Leading Transplant Doctors and Pioneering Cellular Therapy Researchers | BioSpace | 10/9/2019

… sickle cell anemia, thalassemia, lymphoma and leukemia. In addition, attendees will learn about exciting advances in the emerging field of regenerative medicine to potentially treat autism, cerebral palsy, spinal cord injury and more. As the … Healthcare Logistics), Dr. Wise Young ( Rutgers University ), Dr. Elizabeth Shpall (MD Anderson Cancer Center), Dr. Filippo Milano (Fred Hutchinson Cancer Research Center). In addition, attendees will hear from Dr. Alexes Harris who beat cancer thanks …

Healthspan

AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform | BioSpace | 10/30/2019

… of aging and to increase human longevity, announce the publication of a new paper in the peer-reviewed scientific journal Regenerative Medicine . The paper is on the engineering of allogeneic cells to be hypoimmunogenic (universal … product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications …

Gene Therapies: The Pipeline Towards a New Era for Patients | 10/23/2019

healthspan of patients and offer new approaches to treating diseases, with a sizable pipeline in development. Early leaders in the field have focused on rare diseases which continues to open the pathway for other treatments in oncology and infectious and chronic diseases. The panel was moderated by Shyam Patel, PhD, Associate Director, Portfolio Development & Review, California Institute for Regenerative Medicine (CIRM). The panelists were: Michelle Gilson, Principal, Cannacord Genuity Inc …

Health Net

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… over 12 months allowing the necessary time to secure foundational technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… over 12 months allowing the necessary time to secure foundational technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Joe Biden

Biden denied communion over abortion policy - WHYY | 10/30/2019

Biden denied communion for abortion stance By Mark Eichmann October 29, 2019 In this file photo, former Vice President Joe Biden is flanked by Cardinal Gianfranco Ravasi (right) as he arrives to attend a special audience celebrates by Pope Francis with participants at a congress on the progress of regenerative medicine and its cultural impact in the Paul VI hall in Vatican City, Vatican. (Giuseppe Ciccia/Pacific Press) Rev. Robert …

Biden’s abortion shift tests the politics of his faith | Chron | 9/17/2019

Close Image 1 of 4 FILE - In this April 29, 2016, file photo, Vice President Joe Biden shakes hands with Pope Francis during a congress on the progress of regenerative medicine held at the Vatican. Biden has demonstrated a deep public connection to his Catholic faith, dating to the earliest days of his political career. less FILE - In this April 29, 2016, file photo, Vice President Joe Biden shakes hands …

Scott Gottlieb

Scott Gottlieb to speak at Private Label Trade Show | 10/29/2019

Scott Gottlieb to speak at Private Label Trade Show Press enter to search Scott Gottlieb to speak at Private Label Trade Show 10/29/2019 Subscribe Scott Gottlieb Dr. Scott Gottlieb, who served as the 23rd commissioner … and safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs and digital health devices. The agency also promoted policies to reduce death and disease from tobacco, improve food innovation and safety …

Gene therapy coming of age: Opportunities and challenges to getting ahead | 10/2/2019

… grow significantly, with ten to 20 cell and gene therapy approvals per year over the next five years. 4 4. Scott Gottlieb, “Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director … market under an accelerated regulatory review pathway (for example, a regenerative medicine advanced therapy or breakthrough designation by the FDA), which expedites the approval process. The importance of this accelerated process was emphasized in a …

Bill Oldham

Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare | Business Wire | 10/28/2019

Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare . As part of TLI’s efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations. “Our research base, collaborative institutions and long history of innovation align with RenovaCare’s commitment to breakthrough biomedical technologies,” says Bill Oldham, founder and chairman of …

Fostering the Development of Regenerative Medicine and Chronic Disease Medicines: Thought Leadership & Innovation Foundation Expands Fellowships | Business Wire | 6/18/2019

MCLEAN, Va.- With the help of philanthropic support for regenerative medicine and biomedical research, Dr. Robin Robinson, Ph.D., the first director of the Biomedical Advanced Research and Development Authority (BARDA) and former deputy Assistant Secretary … and diabetic wounds to establish a new regenerative medicine program. Bill Oldham, founder and chairman of the Board, TLI, says, “Repair and regeneration of skin cells has become an area of interest for TLI in …

Chaim Lebovits

BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference | Globe Newswire | 10/25/2019

… p.m. Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one meetings to be held throughout the conference. Chaim Lebovits, President and CEO of BrainStorm said, “We are pleased to have the opportunity … U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS …

BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference | Markets Insider | Business Insider | 10/25/2019

… p.m. Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one meetings to be held throughout the conference. Chaim Lebovits, President and CEO of BrainStorm said, “We are pleased to have the opportunity … U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS …

Manisha Narasimhan

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy | PR Newswire | 10/24/2019

… in Dublin, Ireland , is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands … obligation to update these forward-looking statements. CONTACTS: Allergan: Investors: Manisha Narasimhan , PhD (862) 261-7162 Media: Lisa Brown (862) 261-7320 Lisa Kim (714) 246-3843 SOURCE Allergan plc Related Links http://www.allergan.com …

Allergan to Report Third Quarter 2019 Financial Results | PR Newswire | 10/17/2019

… in Dublin, Ireland , is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands … obligation to update these forward-looking statements. CONTACTS: Allergan: Investors: Manisha Narasimhan , PhD (862) 261-7488 Media: Lisa Brown (862) 261-7320 SOURCE Allergan plc Related Links https://www.allergan.com …

Yehiel Tal

CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication’s Industry Relations Committee | 10/22/2019

The Industry Relations Committee represents all aspects of Biofabrication including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization CollPlant delivered a poster presentation at International Conference on Biofabrication in Columbus, Ohio on October 21, 2019 REHOVOT, Israel , Oct. 22, 2019 /PRNewswire/ – CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced the Company’s Chief Executive Officer Yehiel Tal was recently appointed as a member of the Industry Relations Committee …

Corey Orava

Enso Discoveries and Kansas Department of Agriculture will Host the 4th Annual Kansas Veterinary Regenerative Symposium on Saturday, November 9, 2019 | PRWeb | 10/17/2019

… Meeting. Kansas Veterinary Regenerative Symposium The mission of the KVRS has always been to concisely educate the practicing veterinarian about regenerative medicine in such a way that they can immediately implement into their practice. MANHATTAN … patient, so being informed has never been more important,” said Corey Orava, DVM, CSO of Enso Discoveries and Chair of KVRS. This year KVRS will have four speakers from both academia and private practice. The …

Enso Discoveries and Dr. Corey Orava, DVM, Announce a First of its Kind, Patent Pending, Regenerative Medicine Therapy for Veterinarians | Benzinga | 5/17/2019

Corey Orava , DVM, has developed and brought to market a patent pending, affordable, effective, easy-to-use, university-validated Platelet Rich Fibrin (PRF) kit for veterinarians to be used with both equine and companion animals. This latest achievement is a testament to the dedication of the Enso Discoveries team to be the foremost leader in providing affordable, accessible, and scientifically-advanced veterinary regenerative medicine products. Enso Discoveries has advanced this …

Hans Keirstead

ROOT OF SKIN™ Skincare Products Sell Out in Tenth Consecutive Appearance on QVC Japan | PR Newswire | 10/15/2019

… of women with ovarian cancer. “Outstanding market traction, a product that truly works, and a benevolent use of proceeds,” said Hans Keirstead , AIVITA’s Chief Executive Officer. “This sets the stage for global expansion of our … advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity …

AIVITA CEO Dr. Hans Keirstead Honored as One of Canada’s ‘Seven Wonderers’ at Beakerhead Festival | PR Newswire | 10/1/2019

… 1, AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that Chairman and CEO Dr. Hans Keirstead was honored as one of Canada’s seven thought leaders at the Beakerhead Festival … advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity …

Grace Century

Grace Century Celebrates its 9th Anniversary | PRWeb | 10/14/2019

Grace Century Celebrates its 9th Anniversary Share Article Grace Century, an international Angel group and Start-up consultant specializing in Healthcare enjoys 9 full years in business. RAS AL KHAIMAH, United Arab Emirates Grace Century, an international Research and Private Equity Company based out of Ras Al Khaimah, (North of Dubai) U.A.E., enters its tenth year working with companies in the regenerative medicine and the dynamic healthcare IT space. CEO …

Grace Century Celebrates Its 7th Anniversary | PR Newswire | 10/25/2017

Worldwide Offices Grace Century Celebrates Its 7th Anniversary Grace Century, an international private equity firm specializing in Healthcare “Start-ups”, completes 7 years in the United Arab Emirates News provided by Oct 24, 2017, 23:30 … business, researching and vetting healthcare projects and specifically companies in regenerative medicine for its group of “Angel’s”. Grace Century Founded on the principal that a void existed for start-ups and Angels, both in connections …

Scott Wolf

Grace Century Celebrates its 9th Anniversary | PRWeb | 10/14/2019

regenerative medicine and the dynamic healthcare IT space. CEO of Grace Century, Scott Wolf, comments on the current environment: “A perfect storm, whose components we identified years ago, is now finally starting to converge. The birth of 5G, the advances in artificial intelligence (AI), the continued integration of IOT (internet of things), data aggregation, and the “greying of the world’s population” have all come home to the world’s largest economic …

Grace Century Celebrates Its 7th Anniversary | PR Newswire | 10/25/2017

… Al Khaimah , U.A.E., has celebrated entering its eighth year of business, researching and vetting healthcare projects and specifically companies in regenerative medicine for its group of “Angel’s”. Grace Century Founded on the principal that a … other than the two original projects. Commenting on project selectivity, Scott Wolf , CEO of Grace Century said, “In contrast to many firms that deal in this sector, we have chosen only two projects. Our Members …